Jazz Pharmaceuticals PLC
NASDAQ:JAZZ

Watchlist Manager
Jazz Pharmaceuticals PLC Logo
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Watchlist
Price: 126.67 USD 1.25% Market Closed
Market Cap: 7.7B USD
Have any thoughts about
Jazz Pharmaceuticals PLC?
Write Note

Jazz Pharmaceuticals PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jazz Pharmaceuticals PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Income from Continuing Operations
$465.3m
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
31%
Perrigo Company PLC
NYSE:PRGO
Income from Continuing Operations
-$146.9m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Income from Continuing Operations
-$72.6m
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
-3%
G
GH Research PLC
NASDAQ:GHRS
Income from Continuing Operations
-$35.6m
CAGR 3-Years
-329%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cosmo Pharmaceuticals NV
SIX:COPN
Income from Continuing Operations
€75.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-1%
Ovoca Bio PLC
LSE:OVB
Income from Continuing Operations
-€4m
CAGR 3-Years
-5%
CAGR 5-Years
-15%
CAGR 10-Years
7%
No Stocks Found

Jazz Pharmaceuticals PLC
Glance View

Market Cap
7.7B USD
Industry
Pharmaceuticals

Jazz Pharmaceuticals PLC is a dynamic biopharmaceutical company that specializes in developing and commercializing innovative products to address unmet medical needs, particularly in the areas of sleep medicine and neurology. Founded in 2003 and headquartered in Dublin, Ireland, Jazz has successfully built a diverse portfolio of therapies that include treatments for rare and complex conditions like narcolepsy, which affects sleep quality and overall quality of life. The company's flagship product, Xyrem, has seen robust market success, driving revenue growth and allowing Jazz to expand its research and development efforts across multiple therapeutic areas. In recent years, Jazz has capitalized on strategic acquisitions to enhance its pipeline and broaden its therapeutic focus. Notably, the acquisition of GW Pharmaceuticals in 2021 brought a groundbreaking cannabinoid product, Epidiolex, into its offerings, further cementing the company's position in the market. With a strong emphasis on research and innovation, Jazz Pharmaceuticals is not just a player in today’s market but is poised for future growth as it continues to explore novel treatments across various medical conditions. For investors, Jazz presents an intriguing opportunity, combining a solid business model, a commitment to addressing critical health challenges, and a history of strong financial performance that suggests a promising outlook in the competitive biopharmaceutical landscape.

JAZZ Intrinsic Value
360.43 USD
Undervaluation 65%
Intrinsic Value
Price

See Also

What is Jazz Pharmaceuticals PLC's Income from Continuing Operations?
Income from Continuing Operations
465.3m USD

Based on the financial report for Sep 30, 2024, Jazz Pharmaceuticals PLC's Income from Continuing Operations amounts to 465.3m USD.

What is Jazz Pharmaceuticals PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
31%

Over the last year, the Income from Continuing Operations growth was 459%.

Back to Top